Superworth

Pacira BioSciences price to free cash flow PCRX

Market value divided by free cash flow over the last twelve months, since 2016.

Today, Oct 23, 2026
8.1×
10-year median
26.4×
Against its 10-year history
22nd
percentile: 0 is its lowest day, 100 its highest
10-year range
2.9× to 390×
Peer median
8.6×

Pacira BioSciences' price to free cash flow is 8.1× as of Oct 23, 2026.

That is below its ten-year median of 26.4×, lower than on 78% of days in the last ten years.

Over that time it ranged from 2.9× in Aug 2024 to 390× in Feb 2017.

The median for 10 large drugmakers of a similar size is 8.6×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far8.1×5.1×8.5×
20259.2×4.4×10.4×
20244.7×2.9×12.2×
202312.0×9.6×20.7×
202219.1×19.0×45.9×
202127.3×23.5×118×
202091.6×21.4×199×
201932.1×28.0×61.4×
201864.2×62.7×303×
201796.2×88.5×390×
2016288×270×329×

Against its peers

Companies in Drug Manufacturers - General nearest Pacira BioSciences' size, closest first, today.

CompanyPrice to free cash flow
PCRXPacira BioSciences8.1×
ANABAnaptysbion/m
PAHCPhibro Animal Health160×
ANIPANI Pharmaceuticals9.6×
OMEROmerosn/m
AMPHAmphastar Pharmaceuticals7.0×
HRMYHarmony Biosciencesn/m
PBHPrestige Consumer Healthcare9.6×
ABUSArbutus Biopharman/m
NRIXNurix Therapeutics7.5×
COLLCollegium Pharmaceutical2.3×
Peer median8.6×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Pacira BioSciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.